Stryker buys out of OP-1 royalties to Curis:
This article was originally published in Clinica
Executive Summary
Stryker (Kalamazoo, Michigan) is to pay a one-off cash sum of $14m to Curis (Cambridge, Massachusetts) to release itself from the obligation to pay royalties on future sales of its osteogenic protein-1 bone growth factor (OP-1). Stryker will amortise the payment over the next 15 years. The agreement allows Curis to reduce royalty payments it may owe Stryker for sales of the product, which it calls BMP-7 (bone morphogenic protein), in indications other than orthopaedics and dental (eg, kidney disease).